Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain

2008-10-08 アップロード · 45 視聴

Results from Phase 3b Studies with Durezol Dosed Prior to Surgery

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that Durezol™ (difluprednate ophthalmic emulsion) 0.05% is now commercially available. Durezol, which was approved by the U.S. Food and Drug Administration in June 2008, is a topical ophthalmic corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery.

To view Multimedia News Release, go to http://www.prnewswire.com/mnr/durezol/34934/

tag·Sirion Therapeutics,Durezol,Multivu,35319

非会員の場合は、名前/パスワードを入力してください。

書き込む
今日のアクセス
12
全体アクセス
131,588
チャンネル会員数
35

My Video

リスト形式で表示 碁盤形式で表示